Strategic roadmap of milestones that BIEL (ActiPatch/RecoveryRx) could pursue to fully capitalize on the wearables push and a potential Electrome collaboration:
Phase 1: Foundation (0–12 months)
Regulatory Expansion
File for additional FDA indications (e.g., diabetic neuropathy, post-surgical recovery).
Pursue CE Mark expansion in Europe for broader therapeutic claims.
Clinical Validation
Launch new randomized controlled trials (RCTs) demonstrating efficacy in chronic pain, maternal health, and recovery.
Partner with academic centers for AI-driven compliance studies.
Integration Readiness
Develop APIs for ActiPatch/RecoveryRx to integrate with Apple Health, Fitbit, and hospital EHR systems.
Begin pilot collaborations with Electrome for biometric monitoring + therapy bundles.
Phase 2: Market Entry (12–24 months)
Reimbursement Pathways
Secure CMS (Medicare/Medicaid) reimbursement codes for ActiPatch/RecoveryRx as “therapeutic wearables.”
Work with private insurers to include devices in opioid-alternative programs.
Strategic Partnerships
Formalize collaboration with Electrome (or similar firms) to create closed-loop therapeutic systems.
Partner with hospital networks for post-surgical recovery bundles.
Consumer Awareness
Launch direct-to-consumer campaigns highlighting drug-free pain relief.
Position ActiPatch as a “smart therapeutic wearable” rather than a medical patch.
Phase 3: Ecosystem Integration (24–36 months)
AI & Data Platforms
Integrate therapy outcomes into AI dashboards for predictive analytics.
Enable real-time monitoring + intervention loops (detect flare-ups → trigger therapy → track outcomes).
Chronic Disease Programs
Embed ActiPatch/RecoveryRx into diabetes management ecosystems (with glucose monitors).
Expand into maternal health initiatives with bundled wearable packages.
Global Expansion
Target Asia-Pacific markets where wearable adoption is surging.
Leverage WHO and NGO partnerships for pain management in underserved regions.
Phase 4: Leadership Position (36–48 months)
Policy Alignment
Position BIEL as a flagship partner in RFK Jr.’s national wearables initiative.
Advocate for inclusion in federal digital health programs.
Product Diversification
Develop next-gen smart patches with embedded sensors (pain detection + therapy in one).
Explore veterinary and sports medicine applications.
Market Recognition
Establish BIEL as a digital therapeutics leader, not just a device company.
Pursue IPO uplisting or strategic acquisition partnerships.
Strategic Takeaway
This roadmap shows how BIEL can move from FDA-cleared niche devices → reimbursed therapeutic wearables → AI-integrated digital health leader. The Electrome collaboration is the catalyst that transforms ActiPatch/RecoveryRx from standalone patches into smart, data-driven therapeutic ecosystems.
Phase 1: Foundation (0–12 months)
Regulatory Expansion
File for additional FDA indications (e.g., diabetic neuropathy, post-surgical recovery).
Pursue CE Mark expansion in Europe for broader therapeutic claims.
Clinical Validation
Launch new randomized controlled trials (RCTs) demonstrating efficacy in chronic pain, maternal health, and recovery.
Partner with academic centers for AI-driven compliance studies.
Integration Readiness
Develop APIs for ActiPatch/RecoveryRx to integrate with Apple Health, Fitbit, and hospital EHR systems.
Begin pilot collaborations with Electrome for biometric monitoring + therapy bundles.
Phase 2: Market Entry (12–24 months)
Reimbursement Pathways
Secure CMS (Medicare/Medicaid) reimbursement codes for ActiPatch/RecoveryRx as “therapeutic wearables.”
Work with private insurers to include devices in opioid-alternative programs.
Strategic Partnerships
Formalize collaboration with Electrome (or similar firms) to create closed-loop therapeutic systems.
Partner with hospital networks for post-surgical recovery bundles.
Consumer Awareness
Launch direct-to-consumer campaigns highlighting drug-free pain relief.
Position ActiPatch as a “smart therapeutic wearable” rather than a medical patch.
Phase 3: Ecosystem Integration (24–36 months)
AI & Data Platforms
Integrate therapy outcomes into AI dashboards for predictive analytics.
Enable real-time monitoring + intervention loops (detect flare-ups → trigger therapy → track outcomes).
Chronic Disease Programs
Embed ActiPatch/RecoveryRx into diabetes management ecosystems (with glucose monitors).
Expand into maternal health initiatives with bundled wearable packages.
Global Expansion
Target Asia-Pacific markets where wearable adoption is surging.
Leverage WHO and NGO partnerships for pain management in underserved regions.
Phase 4: Leadership Position (36–48 months)
Policy Alignment
Position BIEL as a flagship partner in RFK Jr.’s national wearables initiative.
Advocate for inclusion in federal digital health programs.
Product Diversification
Develop next-gen smart patches with embedded sensors (pain detection + therapy in one).
Explore veterinary and sports medicine applications.
Market Recognition
Establish BIEL as a digital therapeutics leader, not just a device company.
Pursue IPO uplisting or strategic acquisition partnerships.
Strategic Takeaway
This roadmap shows how BIEL can move from FDA-cleared niche devices → reimbursed therapeutic wearables → AI-integrated digital health leader. The Electrome collaboration is the catalyst that transforms ActiPatch/RecoveryRx from standalone patches into smart, data-driven therapeutic ecosystems.
2
